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1. Introduction 
 
1.1 Prostate gland 
In humans, prostate development occurs during the second and third trimester and is 
complete at the time of birth (Lowsley, 1912). The prostate sits under the bladder and is 
located at the base of the penis and in front of the anus. The structure of the prostate is 
that it has a narrow hole through the middle. It is fashioned this way as the urethra, the 
tube which empties urine from the bladder passes through this hole on its way to the end 
of the penis (The Cancer Council Victoria, 2007). The gland enlarges continuously in 
size to reach the adult weight of approximately 20 g by 25–30 years of age (Figure 1.1). 
 
 
 
Figure 1.1: Normal prostate anatomy (Robert et al., 2000) 
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 Similarly to the breast, the prostate is a gland which produces and secretes 
fluids. The prostate also controls the flow of these fluids. Semen which was ejaculated 
from the penis during sexual climax (orgasm) was produced by the cells which line the 
prostate gland. The prostate also produces some of the fluid in the semen. The prostate 
also helps separate the urine from the semen. The way the semen is found to be in the 
liquid form was because of the prostate specific antigen (PSA). PSA is an enzyme, 
which is produced primarily by cells lining the ducts and the acini of the prostate gland. 
The PSA is found in the form of a glycoprotein (Strax, 2008). 
 The prostate overall structure however is the greatest setback. The wrap around 
structure around the urethra becomes problematic if the prostate swells or enlarges. 
Enlargement of the prostate could occur in man of all ages and could be cause by 
prostate infection, commonly known as prostatitis. It could also be caused by benign 
growth. In both cases, it will cause pain, discomfort and problems in urination (Strax, 
2008). 
 
1.2 Prostate Diseases 
Generally the occurrence of prostate associated problems increase with ages. 
Symptoms or problems of the following are relatively common. 
 
 Difficulty in getting the urinary flow started, especially when a person is in a 
hurry 
 Difficulty stopping the urine flow  
 Requires longer time, due to the urine stream is weak, or it stops and starts 
 Dribbling of urine after a person have finished 
 Frequency of going to the toilet throughout the day, even though there is not 
much urine to pass 
3 
 
 Getting up at night to go to the toilet, a person used to sleep through.  
 Needing to go urgently at all times 
 An unfinished feeling or that there is need to go again repeatedly, although 
nothing is produced 
 Pain or a burning sensation when urinating 
 Blood in the urine (The Cancer Council Victoria, 2007) 
 
 Due to the structure of the prostate (Strax, 2008) the prostate will be a source of 
three of the major health problems which affects men. The following are the major 
prostate disease: 
 Benign prostatic hyperplasia (BPH); commonly known as the prostate 
enlargement. It is one of the most common benign tumors in men 
 Prostatitis; the prostate inflammation and the most common cause of urinary 
tract infections in men. This is a highly painful condition 
 Prostate cancer, the most common cancer in men (Walsh and Worthington, 
2002). 
 
BPH is commonly found in most men at the age of sixty or older. BPH is a non-
malignant enlargement of the prostate effecting about 50% of men of that particular age 
category. This enlargement however is normal, and is caused by aging and is rarely life 
threatening but may produce up-setting symptoms (Rubenstein and McVary, 2008). 
BPH is not prostate cancer, as BPH and prostate cancer are two separate diseases which 
are formed in different parts of the prostate. Having developed BPH does not indicate 
that a man is more or less likely to acquire prostate cancer. The difference in prostate 
cancer and BPH is that prostate cancer initiates at the outer, marginal zone of the 
prostate and is growing outward and invades tissues surrounding it and that is primarily 
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the reason that it seldom produces symptoms until it is far advanced. Meanwhile BPH 
on the other hand begins in a small area of the inner prostate known as transition zone 
which is a ring of tissues that make a natural circle surrounding the urethra. While 
prostate cancer grows outwards, BPH grow inwards toward the prostate’s core and 
constantly tightening around the urethra and interfering with urination, which provides 
many symptoms. BPH is a very common condition and it is not cancerous, but it can 
mimic cancer (Walsh and Worthington, 2002). BPH can be treated with medications or 
surgery. The medications will be able to alter hormone levels, or can relax or reduce the 
size of the prostate, hence reducing the pressure on the urethra. Medication may take 
time like months before the condition improves. Surgery procedures to remove part of 
the prostate could be taken to stop the squeezing of the urethra. Laser and microwave 
treatments could also be applied. (The Cancer Council Victoria, 2007). 
Prostatitis in men is the most prevalent cause of urinary tract infection. It is 
anticipated that a quarter of all men who visits a doctor for urological problems have tell 
tale signs of prostatitis. In general, there are four conditions, which are categorized as 
“prostatitis”. The first, two acute and chronic bacterial prostatitis, as the name suggest, 
are caused by bacteria and are not common but easily treated. These two prostatitis are 
accompanied by symptoms such as fever, chills, severe burning on urination, increased 
frequency of urination, and, in certain cases, a life-threatening infection in the 
bloodstream. 
The third form of prostatitis is called chronic prostatitis or chronic pelvic pain 
syndrome. The actual causes these forms of prostatitis are not known and medications 
like antibiotics do not help at all. Medications are mainly targeted at relieving 
symptoms, with muscle relaxants such as alpha-blockers and other drugs, which ease 
muscle tension in the prostate and make urination easier. The other form of prostatitis is 
called the asymptomatic inflammatory prostatitis, which produces no symptoms and is 
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usually found by chance, when inflammatory cells are found in the prostatic fluid or 
inflammation is detected on a prostate biopsy. Again, in the case of prostatitis, it is not a 
cancer (Walsh and Worthington, 2002), treatment is with the help of antibiotics and 
consumption of medication may need to persist for several months. Some men may also 
need surgery to stop the swollen prostate from pressing on the urethra (The Cancer 
Council Victoria, 2007). 
For the detection of those prostate diseases, the doctor normally collect a patient’s 
urine and thoroughly exam his prostate gland. To check the prostate gland, the doctor 
undergoes digital rectal examination, which involves inserting a well-lubricated gloved 
finger into the rectum to check for any abnormalities of the gland. Meanwhile prostate 
specific membrane antigen (PSMA) test could also be carried out where a blood tests to 
look for this glycoprotein compound in the blood, which is produced by the prostate. 
Once there is a high level of detection it could be probable be prostate cancer but the 
doctor needs to carry out more tests to be certain. A biopsy could be carried out once 
PSMA test or digital rectal examination is abnormal. This involves an ultrasound probe 
being placed in the rectum to find areas of the prostate which are abnormal. Samples 
(usually six or more) of the prostate are subsequently taken and sent to be observed 
under the microscope. This procedure can be certain to diagnose if one has prostate 
cancer. The biopsy will also provide insights of how fast the cancer may develop and 
how much of a threat it may be (The Cancer Council Victoria, 2007). 
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1.3 Prostate Cancer 
1.3.1 History of Prostate Cancer 
 
The history of prostate cancer spans for about 200 years from the recognition of 
the disease to the development of the three primary types of treatment which are 
surgery, radiation and hormonal manipulation. Random cases of prostate cancer were 
noted by physician as way back as 1817. In the early days, histological examination was 
not yet in clinical use and hence, diagnoses were made at autopsies. Later on in 1853, 
the first case of prostate cancer established by histological examination was reported by 
Adams, a surgeon at The London Hospital, where a 59 year old man with a scirrhous 
(hard and firm) tumor at the prostate gland. The prostate cancer largely unrecognized 
until the turn of the last century, when prostatic adenectomy for urinary obstruction 
became widely performed resulting in more specimen available for histological 
examination.  
In the year 1898, Fuller performed complete prostate removal together with a 
bladder neck resection and then patient bladder function recovered. After the discovery 
of X-ray and its applications, in 1909 Minet from Paris placed a radium tube in a 
catheter to irradiate prostate cancer and subsequently in 1913 Pasteau and Degrais 
reported a 3 year cure using this method. In the early 1900s experiments in animals 
established the relationship of the pituitary and testis as well as their effects on the 
prostate and this sparked the beginning of the research on the treatment through 
hormonal manipulation. All these studies subsequently lead to the major discovery of 
the dramatic effects of castration and estrogen administration on prostate cancer cells in 
1941 by Huggins at the University of Chicago. During the period of 50 years, Huggins 
reported more than 230 scientific articles, mostly on the effects of hormones on cancer, 
with emphasis on the prostate and breast. 
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 In 1966 he shared the Nobel Prize in physiology and medicine with Rous, who 
developed the first virally induced solid tumor in animals, called the Rous-chicken 
sarcoma (Lytton, 2001). 
 
1.3.2 Definition of Prostate Cancer 
 
Prostate cancer is a form of cancer that develops in the prostate. The cells are 
known to mutate and there is uncontrollable growth. Prostate cancer is the primary 
cause of cancer death and is the most common major cancer in men. A common fact is 
noted that when prostate cancer is small and curable, it is often also silent where it 
produces no tell tale signs. Hence, routine testing is very important where the cancer is 
detected as early as possible and once if it is detected too late, the prostate cancer can be 
often lethal and the symptoms are often painful if the disease is allowed to run its 
course. However if it is detected early prior to the cancer cells spreading beyond the 
wall of the prostate, prostate cancer can be cured with surgery or radiation (Walsh and 
Worthington, 2002). 
 In some cases, some men with small and slow-growing tumors, a process called 
expectant management which means following the disease closely may be a safer 
option. With the advances of technologies, treatment and successful rate of curing 
prostate cancer is better and with fewer side effects. However, although in some cases 
the cancers are incurable, the metastasis of the cancer cells can be contained with the 
advancement in the medical technology.  
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 In prostate cancer the key to a better chance of recovery is as follows: 
• Prevention—to ward off prostate cancer entirely, or at least delay its onset for 
decades. 
• Earlier diagnosis—with the help of highly sensitive tests and sophisticated 
models for analyzing the results, detecting prostate cancer at the earliest and 
most curable stages yet. 
• Better treatment for localized disease—expanding and refining effective 
treatments, and working to minimize side effects even further. 
• Better control of advanced disease. (Walsh and Worthington, 2002). 
 
 
1.3.3 Genetics of cancer 
 
Similar to other cancers, prostate cancer also develops due to the consequences 
of genetic changes. There are quite a number of putative genes that have been isolated 
for the development of breast, ovarian (BRCA1, BRCA2) and colon cancer (hMLH1, 
hMSH2) but however, the etiology and pathogenesis of prostate cancer continues to be 
largely unknown. This is also due to the fact that prostate cancer is such a 
heterogeneous disease. The diversity of prostate cancer with the stepwise transition 
from benign cells through prostatic intraepithelial neoplasia (PIN), invasive carcinoma, 
the development of metastases to hormone refractory disease make this an interesting 
disease to study but also a difficult disease to cure. Many works have been published on 
clinical prognostic factors but with advanced development in molecular genetics, the 
genetic code analysis that will in the future give both prognostic information and targets 
for therapeutic intervention.  
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At present, the available prognostic factors have recently been ranked by a 
multidisciplinary group of clinicians, pathologists and statisticians and they are divided 
in three categories as follows: 
 Category I: Factors of prognostic importance and are used frequently on a daily 
basis in patient management. These are inclusive of the preoperative prostate 
specific antigen (PSA), TNM stage, Gleason grade and surgical margin status.  
 Category II: Factors that have been comprehensively studied but the importance 
remains to be validated statistically, e.g. tumor volume, histological type and 
DNA ploidy.  
 Category III: All factors insufficiently studied to demonstrate their prognostic 
value: examples would be oncogenes, tumor suppressor genes and apoptosis 
genes, as well as perineural invasion, neuroendocrine differentiation microvessel 
density, nuclear roundness and chromatin texture (Bott et al., 2003). 
 
1.3.4 Signs and symptoms 
 Prostate cancer could be identified with three different stages namely the early-
stage disease, locally advanced disease and advanced disease. In the early-stage disease, 
patient with organ-confined prostate cancer most commonly without symptoms while 
patient with a large component of benign prostatic hyperplasia could be identified with 
bladder outlet obstruction unrelated to prostate cancer. In the case of locally advanced 
disease, bladder outlet obstruction is mainly the sign of locally advanced prostate cancer 
however there are few cases with locally advanced disease present with hematuria, 
urinary tract infections, and irritative voiding symptoms secondary to bladder outlet 
obstruction. Lastly, in the case of advanced disease there are rare instances where 
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patient with bulky lymph node metastasis may present with bilateral lower-extremity 
edema (Moul et al., 2008). 
 
1.3.5 Screening and diagnosis 
 
 Prostate cancer could be screened using prostate specific membrane antigen 
(PSMA) and digital rectal examination (DRE). With such screening, this has increases 
the prostate cancer detection. With this, prostate cancer is detected at earlier stages, 
when they are potentially curable. Most prostate cancers were undetected until it 
produces local symptoms or distant metastases. The discovery at this stage is often too 
late and incurable. 
The digital rectal examination could possible detect nodularity or induration, and 
this is followed by a biopsy. Even with the detection of such irregularities using DRE, 
from the subsequent biopsy procedure, it only leads to a diagnosis of prostate cancer in 
only 15% to 25% of cases. Although such DRE detection is neither accurate nor 
sensitive for prostate cancer detection, it is however that abnormal DRE is associated 
with a fivefold increased risk of cancer present at the time of screening. PSA is a serine 
protease produced by the prostatic epithelium and secreted in large quantities through 
the seminal fluid. PSA level in the serum could be increased through inflammation of 
the prostate, urinary retention, prostatic infection, benign prostatic hyperplasia, prostate 
cancer, and prostatic manipulation. The overall sensitivity for PSA levels ranges from 
50% to 70% but this depends on the threshold used, and it is not as specific, and in 
addition, it does not allow for differentiation between indolent and aggressive disease. 
A more worthwhile approach for PSA screening may be to use the rate of rise in PSA 
(PSA velocity) in combination with the absolute PSA value. This approach has been 
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shown to be useful recently in the form of age-adjusted PSA velocity, but accepted 
guidelines are still controversial (Moul et al., 2008). 
 
1.3.6 Prognosis 
 
The most common and widely used staging system is the TNM system (Table 
1.1). For this system, T1 and T2 are tumors, which are limited to the gland while T3 and 
T4 are the tumor having a local extension. 
Table 1.1: TNM staging system of prostate cancer. 
Localised disease 
T1a Tumor incidental histologic finding in ≤ 5% of resected tissue: not 
palpable 
T1b Tumor incidental histologic finding in ≥ 5% of resected tissue 
T1c Tumor identified by needle biopsy (e.g. because of elevated PSA level) 
T2a Tumor involves one-half of one lobe or less 
T2b Tumor involves more than one-half of one lobe but not both lobes 
T2c Tumor involves both lobes 
Local extension 
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumor invades seminal vesicle(s) 
T4 Bladder invasion, fixed to pelvic side wall, or invasion of adjacent 
structures 
Metastasic disease 
N1 Positive regional lymph nodes 
M1 Distant metastasis 
The management of patients with prostate cancer differs widely and is highly 
reliant upon the patient’s age, overall health, and tumor risk assessment. The disease 
development process can be varied; it can be incidental that will not result to cancer-
specific mortality, to a case of very aggressive, resulting in early widespread metastatic 
disease and death. 
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Patients with a low Gleason score (2– 4) that has clinically localized prostate 
cancer treated conservatively (observation or hormonal therapy alone), have a small risk 
of death from their cancer within 15 years (4%–7%). Meanwhile, those with poorly 
differentiated tumors (Gleason score 8–10), have a higher risk of death cause by 
prostate cancer than of any other causes, even when the cancer is diagnosed in the 
eighth decade of life. Besides that, if a man prior to sixty years old diagnosed with a 
clinically localized prostate cancer with a Gleason score of 8 to 10 and is left untreated, 
that patient has an 87% risk of dying of the disease within 15 years (Moul et al., 2008). 
1.4 Prostate specific membrane antigen (PSMA) 
1.4.1 Structure of PSMA 
The PSMA gene consists of 19 exons that span 60 kb of genomic DNA. This 
gene encodes a type II transmembrane protein with a short NH2-terminal cytoplasmic 
tail (19 amino acids), a single hydrophobic trans-membrane domain (24 amino acids), 
and a large extracellular domain (707 amino acids) at the COOH terminus (Figure.1.2), 
(Israeli et al., 1993; O'Keefe et al., 1998). The extracellular domain of PSMA is highly 
glycosylated, with linked oligosaccharides accounting for up to 25% of the 
molecular weight of the native protein (Holmes et al., 1996). Regions within this 
domain share modest degrees of homology with the transferrin receptor (TfR) (Israeli et 
al., 1993), and with members of the M28 family of cocatalytic aminopeptidases 
(Rawlings et al., 1997). Although the TfR has only a vestigial catalytic site, PSMA is 
known to possess both N-acetylated, -linked acidic dipeptidase (NAALADase) and 
folate hydrolase (FOLH) activities (Pinto et al., 1996). 
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Figure 1.2: Schematic diagram of prostate-specific membrane antigen (PSMA) 
structure. PSMA is a type II transmembrane protein with a short NH2-terminal 
cytoplasmic domain (CD), a hydrophobic transmembrane region (TM), and a large 
extracellular domain (ED). The CD contains an endocytic targeting motif and filamin A 
(FLNa) binding site (A). The large ED is highly glycosylated with nine predicted N-
glycosylation sites (Y). The ED contains two domains of unknown function that span 
amino acid residues 44–150 (B) and 151–274 (D), proline- and glycine-rich regions that 
span amino acid residues 145–172 and 249–273, respectively (C and E), a catalytic 
domain that spans amino acid residues 274–587 (F), and a final domain of unknown 
function (amino acids 587–750) to which a helical dimerization domain (amino acids 
601–750) is localized (G) (Israeli et al., 1993; O'Keefe et al., 1998). 
 
These two related peptidase activities
 
hydrolyze -peptide bonds between N-
acetylaspartate and glutamate
 
in the abundant neuropeptide N-acetylaspartylglutamate 
(NAAG)
 
and the -glutamyl linkages in pteroylpolyglutamate, respectively.
 
Thus this 
enzyme has been referred to alternatively as glutamate
 
carboxypeptidase II (GCP-II) and 
folate hydrolase 1 (FOLH1).
 
The enzymatic activity of PSMA is largely inhibited by 
phosphate,
 
even at millimolar concentrations (Slusher et al., 1999), and is dependent 
on
 
glycosylation and dimerization for proper function (Ghosh et al., 2003).
 
In contrast to 
the large extracellular domain, the cytoplasmic
 
tail of PSMA consists of just 19 amino 
acids. In spite of its
 
diminutive stature, the cytoplasmic domain interacts with a
 
number 
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of proteins and has a major impact on the localization
 
and molecular properties of 
PSMA (Anilkumar et al., 2003). 
 
1.4.2 Dimerization of PSMA 
Homodimerization is a fundamental feature of many transmembrane
 
receptors. 
Induction of homodimer formation is often induced
 
by ligand binding, which is in turn 
necessary for mediating
 
the cellular response of the receptor (Schlessinger et al., 2002). 
The TfR is an archetypal
 
example of one such receptor. This type II transmembrane 
protein
 
is involved in regulating cellular iron homeostasis through
 
binding and 
internalization of iron-laden transferrin (Aisen et al., 2004). PSMA shares homology 
with the TfR at the levels of both amino
 
acid identity and domain organization 
(Mahadevan et al., 1999).  
Like the TfR, PSMA
 
is expressed as a noncovalently linked homodimer on the 
cell
 
surface (Lawrence et al., 1999; Schülke et al., 2003). This dimerization is 
apparently mediated by
 
epitopes within the large extracellular domain, because 
truncated versions of PSMA lacking the cytoplasmic and transmembrane domains
 
are 
still capable of interacting. PSMA dimerization is critical
 
to maintaining the 
conformation and enzymatic activity of PSMA
 
(Schülke et al., 2003). Although the 
possibility has yet to be addressed fully,
 
the similarity between PSMA and TfR at the 
amino acid and structural
 
levels, combined with the common dimerization requirement, 
may
 
suggest that these proteins share similar receptor and ligand
 
transport functions.
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1.4.3 Potential role of PSMA enzyme activity 
 
The prostate gland is composed mainly of stromal, epithelial,
 
and 
neuroendocrine cells. The dynamic balance of cell proliferation,
 
differentiation, and 
apoptosis in general maintains the cellular
 
and tissue homeostasis. This balance is 
generated by the continuous
 
cross talk among these cell populations (Sung et al., 2002). 
For this purpose, epithelial and stromal cells secrete various types of growth
 
factors, 
chemokines, and neuropeptides (Wong & Wang, 2000). Deregulation in
 
this paracrine 
communication can result in derangement of the
 
prostate gland, such as benign prostate 
hyperplasia and prostate
 
carcinoma (Dawson et al., 2004). For example, the peptidase 
NEP normally acts
 
to inhibit the migratory properties of prostate epithelial cells.
 
NEP 
achieves the inhibition of prostatic epithelial cell migration
 
by cleaving critical 
neuropeptides such as bombesin and endothelin
 
and thereby prevents the relay of signal 
transduction mediated
 
by G protein-coupled receptors (Sumitomo et al., 2000). Like 
NEP, PSMA is also a type II transmembrane glycoprotein
 
with cocatalytic 
metallopeptidase activity. The increased expression
 
of PSMA in prostatic 
adenocarcinoma may indicate a role in the cleavage of signaling molecules involved in 
maintaining prostate
 
gland architecture and function. The overexpression of PSMA 
could potentially
 
disturb the growth balance of the prostate gland. 
1.4.4 Genomic properties 
 PSMA expression in prostate cancer is significantly higher than in benign 
prostate hyperplasia or the normal prostate and is greater in prostate cancer with a 
higher Gleason score (Marchal and Ghosh et al., 2004), suggesting that the regulatory 
elements controlling PSMA expression become more active as prostate cancer 
progresses.  
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There are at least three PSMA variants produced by alternative splicing: PSM', 
PSM-C, and PSM-D. Interestingly, the ratio of full-length PSMA to variant PSM', 
which lacks nucleotides 114 to 380 of the PSMA cDNA and, as a result, is located in 
cytoplasm, increases as normal prostate progresses to the tumor (Su et al., 1995). 
To date, two transcription regulatory elements have been characterized: the 1.2-
kb promoter upstream of the PSMA-encoding gene (FOLH1) and the PSMA enhancer 
core (PSME) in the third intron of FOLH1. PSME exhibits high activity only in PSMA-
positive LNCaP and C4-2 cells; very low activity in PC-3 cells; and no activity in other 
PSMA-negative cells tested (Watt et al., 2001, Lee et al., 2002). Consistent with PSMA 
expression, PSME is also negatively regulated by androgens, so it exhibits a much 
higher activity at low levels or in the absence of androgens (Wright et al., 1996, Watt et 
al., 2001), making PSME a strong candidate for mediating virus replication or 
expressing exogenous cytotoxic genes in hormone-refractory prostate cancer. 
 
1.5 Polymerase Chain Reaction (PCR) 
 The polymerase chain reaction is a selective amplification of a particular region 
or fragment of a DNA molecule. In order for a PCR to be carried out the border 
sequence of the region must be known. This is because of two short oligonucleotide 
flanking the fragment of interest is need for the amplification and this short 
oligonucleotide is known as primers. The primers delimit the region that would be 
amplified. Amplification is normally being conducted using DNA I polymerase enzyme 
from Thermus aquaticus. Taq polymerase the enzyme from Thermus aquaticus is 
resistant to heat denaturation. 
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 The overall procedure begins with the addition of enzyme to the primed DNA 
template and incubated to produce new complementary strands. This is the heated to   
94 °C so the newly synthesize strand will separate and this is subsequently cooled to let 
more primers to hybridize the respective position. This process of denaturation, 
hybridization and synthesis is repeated 25 to 30 times resulting hundreds of millions of 
copies amplified (Brown, 2002) 
 
1.6 Overlap extension PCR 
Overlap extension polymerase chain reaction is a type of PCR, which helps to 
produce polynucleotides from smaller fragments (Higuchi et al., 1988). 
The following diagram is an overview of the overlap PCR: 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The process of overlap extension polymerase chain reaction. 
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 PCR was used to amplify the smaller fragments of the polynucleotide that was to 
be formed. When PCR for the carried out, the primers used to amplify one of the 
fragment should by synthesis with part of the sequence of the other fragment, hence 
there would be part of an overlapping region. Subsequently, both of these products were 
used as a template for a PCR. The fragments are denatured and they anneal at the 
overlapping regions. This combination of fragment was subsequently extended. The 
complete polynucleotide was then used as a template for another PCR reaction to 
amplify this complete polynucleotide (Miesfeld, 2001). 
 
1.7 TA Cloning 
The procedure of cloning DNA fragment into a plasmid vector is a regular 
procedure in recombinant DNA technology. It is known that cloning methods can be 
divided into two main classes, depending on if ligase is use. Among the two methods, 
commonly used method for cloning is the method that requires the use of DNA ligase to 
link the compatible ends of the DNA fragment and the linearized plasmid, forming a 
single cyclic molecule that is capable of autonomous replication in host cells. 
TA cloning is among the easiest and most effective way of the cloning of PCR 
products as this approach takes advantage of the terminal transferase activity of certain 
thermophilic DNA polymerases, like for example the Thermus aquaticus (Taq) 
polymerase. Taq polymerase is known to have non-template dependent activity, which 
adds a single adenosine to the 3'-ends of a double stranded DNA molecule. With this, 
the molecules PCR amplified by Taq polymerase contains single 3'-A overhangs. With 
this, the use of a linearized “T-vector” which has single 3'-T overhangs on both ends 
permits direct, high-efficiency cloning of PCR products which is facilitated by being 
complement between the PCR product 3'-A overhangs and vector 3'-T overhangs.  
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This strategy is commonly referred to as “TA cloning.” This strategy is rather 
simple and much efficient than blunt-ended ligation for the cloning of PCR products 
(Zhou and Sanchez, 2000). 
 
1.8 Expression system 
The need to have functional studies like protein-protein interaction experiments, 
enzyme kinetics studies, functional studies of the protein, structural studies like protein 
crystallization and protein structure study and as well as production of antibodies for 
further experiments has lead to the expression recombinant protein. There are two main 
systems for the expression of recombinant protein. The two systems are the prokaryotic 
(bacterial) or eukaryotic (usually yeast or mammalian cell) system. 
 
1.8.1. Bacterial expression system 
 The bacterial expression system is the use of prokaryotic cells as an expression 
system. Escherichia coli, a prokaryotic cell is among the most popular hosts in the 
production of recombinant proteins. The E. coli is in favour because of its simplicity, 
safety, and known genetic properties, which is a major asset. The capability of 
transformation of E. coli with foreign DNA is an easy with well-established genetic 
manipulation method. With the advantage of fast propagation, generations of stable cell 
lines are a quick process. The most important advantage of E. coli, however, is its 
capability to produce proteins in large amount and to grow very quickly in comparison 
to other cell lines like mammalian cells. 
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 However, the application of E. coli for production of complex molecules like 
heterodimers, molecules containing complex disulfide bonds, or glycosylated proteins is 
still a problem. Besides that, over expression of recombinant genes often results in 
formation of inactive protein aggregates (inclusion bodies) from which biologically 
active proteins can only be obtained through complicated and costly denaturation–
refolding processes. The other major setback of the usage of E. coli as an expression 
system is difficulty in recovering substantial yields of correctly folded proteins 
(Leonhartsberger, 2006). 
 
1. 8.2 Pichia Pastoris expression system 
The expression systems foreign gene by yeasts is known to be efficient and 
economical and becomes a source of a different of higher eukaryotic proteins which are 
important academically and commercially. Yeasts has both the microbial growth and 
genetic manipulation advantages of E. coli and an eukaryotic environment which allows 
many eukaryote-specific posttranslational protein modifications such as proteolytic 
processing, folding, disulfide bridge formation, and glycosylation. E. coli has the ability 
to produce eukaryotic foreign proteins at high levels; however with the absence of these 
eukaryotic post transcriptional modifications, this causes the proteins to be insoluble 
and inactive. This is why, for eukaryotic proteins that are needed in a biologically active 
and/or native form, in vitro refolding procedures have proven to be inefficient, hence a 
eukaryotic expression system is much desirable. 
The Pichia pastoris which is methylotrophic yeast has two key advantages as a 
host for the production of foreign proteins. The first is the promoter used to transcribe 
foreign genes that is derived from the methanol-regulated P. pastoris alcohol oxidase I 
gene (AOX 1). This is where cells that are exposed to methanol as the sole carbon 
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source, transcription initiation at the AOX 1 promoter (AOX l p) is highly efficient and 
comparable to that of promoters derived from highly expressed glycolytic pathway 
genes. The second key advantage of P. pastoris is that it is not a strong fermenter, 
which is beneficial as yeast fermentation, generates ethanol, where in high-density 
cultures; it can rapidly build to toxic levels. Besides that, in the case of secreted 
proteins, the concentration of a foreign protein in the medium is roughly proportional to 
the concentration of cells, hence a high-cell density fermenter culture is need and         
P. pastoris expression strains are relatively easy to culture at cell densities of -100 
g/liter, dry cell weight, or more. (Cregg, 1999). 
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1.9 Objectives  
This project is a continuation as a part of research project started by previous 
student. Due to the large size of this particular PSMA gene, it was divided into three 
fragments namely G1, G2 and G3. In the previous work, G2 and G3 have been 
constructed. The G1 fragment of PSMA gene failed to be joined, hence six sub-
fragments namely fragment a, b, c, d, e, and f need to be overlapped in order to obtain   
G1 fragment. So in order to obtain the full length of this gene, these fragments need to 
be overlapped.  
The project primarily aims would be: 
1. Construction of the G1 fragment of the PSMA gene. 
2. Amplification and overlapping of G1, G2 and G3 fragments of PSMA gene.  
3. Construction the full length of PSMA gene and amplification.  
4. Cloning of the PSMA gene in the E. coli.  
5. Expression of PSMA gene in the Pichia Pastoris recombinant expression 
system. 
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2. Materials & Methods: 
 
2.1 Overlapping PCR 
For overlapping PCR, a master mix containing its reagent was carried out in a 
1.5 ml microcentrifuge. Overlapping PCR was carried out in a 25 μl reaction containing 
1× MgSO4 free Pfu buffer (Fermentas, Canada), 1.5 mM MgSO4, 200 μM per each 
dNTP (Fermentas, Lithuaya) (dATP, dTTP, dCTP, and dGTP), 1.0 to1.5 unit of Pfu 
polymerase (Fermentas, Canada), autoclaved distilled water, and ~100 ng of  template 
DNA. 
 
2.1.1 Optimization of overlapping PCR 
The quantity of the Pfu polymerase enzyme used ranged from 1 unit to 1.5 units 
for one reaction. There were two PCR programs used in this project, each program was 
used based on the fragment size. 
 
2.1.1.1 Fragment less than 1500bp 
Fragment under the size of 1500bp was overlapped under the following 
conditions using the PCR machine (Peltier Thermal Cycler MJ Research): samples were 
subjected to 16 cycles of denaturation at 95ºC for 3 min, annealing at 60ºC for 1 minute, 
extension at 72ºC for 1 minute, and a final cycle of elongation for 5 minute at 72ºC. 
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2.1.1.2 Fragment more than 1500bp 
Fragment over the size of 1500bp was overlapped under the following 
conditions using the PCR machine (Peltier Thermal Cycler MJ Research and PCR 
system 2400): samples were subjected to 16 cycles of denaturation at 95ºC for 3 minute, 
annealing at 60ºC for 1 minute, extension at 72ºC for 10 minute, and a final cycle of 
elongation for 10 minute at 72 ºC. 
 
 
2.1.2 PCR amplification 
For PCR amplification, a master mix containing its reagent was carried out in a 
1.5 ml microcentrifuge. PCR amplification was carried out in a 25 μl reaction 
containing 1× MgCl free Taq buffer (EURx , Poland), 1.5 mM MgCl2, 200 μM per each 
dNTP (Fermentas, Lithuaya) (dATP, dTTP, dCTP, and dGTP), 0.4 μM for each primer, 
1-2 unit of Taq polymerase (EURx , Poland), autoclaved distilled water, and 2 μl of  
overlapping PCR product. 
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2.1.2.1 Optimization of PCR 
The quantity of the Taq polymerase enzyme used ranged from 1 unit to 2 units 
for one reaction. The following are the primers combination and the fragments 
amplified. 
Fragment  Primers Primers Sequence 
G1 SfiPSMA-F 
PSMA-961R 
5'-cttcgggcccagccggccgatgtgcaatctccttcacgaaac-3' 
5'-gaagattccaaccatctggataggacttcac-3' 
G2 PSMA-961F 
PSMA-1741R 
 
5'-tccagatggttggaatcttcctggaggtggt-3' 
5'-gccactgaactctggggaaggacttttttta-3' 
G3 PSMA-800F 
PSMAfacXa-
Not1R 
 
5'-cttccccagagttcagtggcatgcccaggat-3' 
5'-agctggcggccgcgcggccttcaatggctacttcactcaaa-3' 
 
G1-G2 SfiPSMA-F 
PSMA-1741R 
 
5'-cttcgggcccagccggccgatgtgcaatctccttcacgaaac-3' 
5'-gccactgaactctggggaaggacttttttta-3' 
G2-G3 PSMA-961F 
PSMAfacXa-
Not1R 
 
5'-tccagatggttggaatcttcctggaggtggt-3' 
5'-agctggcggccgcgcggccttcaatggctacttcactcaaa-3' 
 
G1-G2-
G3 
SfiPSMA-F 
PSMAfacXa-
Not1R 
5'-cttcgggcccagccggccgatgtgcaatctccttcacgaaac-3' 
5'-agctggcggccgcgcggccttcaatggctacttcactcaaa-3' 
                              Table 2.1: Primer combination and the amplified products 
 
There were two PCR programs used in this project, each program was used was based 
on the fragment size. 
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2.1.2.1.1 Fragments more than 1500bp 
 Fragments more than 1500bp was amplified using the following conditions in 
the PCR machine (PCR system 2400): the samples were subjected to 35 cycles of 
denaturation at 95 ºC for  3 minutes, annealing at 50 ºC for 1 minutes, extension at       
72 ºC  for 2 minutes 30 seconds, and a final cycle of elongation for 5 minutes at 72 ºC. 
Or amplification was performed under the following conditions in the PCR 
machine (PCR system 2400): the samples were subjected to 35 cycles of denaturation at 
95 ºC for 3 minutes, annealing at 55 ºC for 1 minutes, extension at 72 ºC  for 2 minutes 
30seconds , and a final cycle of elongation for 5 minutes at 72 ºC. 
 
2.1.2.1.2 Fragment less than 1500bp 
Fragments less than 1500bp was amplified using the following conditions in the 
PCR machine (Peltier Thermal Cycler MJ Research): the samples were subjected to 32 
cycles of denaturation at 95 ºC for 3 minutes, annealing at 55 ºC for 45 seconds, 
extension at 72 ºC for 1 minutes, and a final cycle of elongation for 5 minutes at 72 ºC. 
Or amplification was performed under the following conditions in the PCR 
machine (Peltier Thermal Cycler MJ Research): the samples were subjected to 35 cycles 
of denaturation at 95 ºC for 3 minutes, annealing at 60 ºC for 45 seconds, extension at 
72 ºC for 1 minutes and 30 seconds, and a final cycle of elongation for 5 minutes at 72 
ºC. 
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2.2 Gel electrophoresis 
 
A 1% agarose gel was prepared mixing agarose powder (Vivantis, USA) and 
TBE Buffer (89 mM tris base, 89 mM boric acid, 2 mM EDTA) and was subsequently 
boiled using the microwave until all agarose powder was fully dissolved. The molten 
agarose was cooled down until it is only warm to touch and then Ethidium bromide was 
added in and mixed with the solution. The molten agarose was then poured into the 
mould and caster to be further cooled down and to let it solidify. Once solidify, the gel 
was immersed in TBE buffer in the gel electrophoresis tank. PCR sample was then 
mixed with 6× loading dye at the ratio of 5 units of samples to 1 unit of dye. Each 
sample was loaded in the wells separately. A DNA marker 100bp (seegene, Korea), 1kb 
(Promega, USA), was also loaded in the well. The gel was then electrophoresis at 120 
volts for 20 minutes. The gel was then removed and visualised under ultraviolet light. 
 
2.3 Gel Extraction 
Gel extraction was carried out in this research to excise expected band of the 
PCR samples. All gel extractions that were carried out in this research were done using 
QIAquick Gel Extraction Kit from USA according to manufacturer's protocol.  
 
2.4 Cloning  
2.4.1 Competent Cell Preparation 
2 μl of JM109 High Efficiency Competent Cells was added to 10 ml of sterile 
LB broth (Pronadisa, Spain) in a universal bottle under sterile condition using aseptic 
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techniques. The universal bottle was then capped loosely and was secured onto a 37 °C 
shaking bath at 220 rpm to be incubated overnight (16 hours). Then 1 ml of the 
overnight culture was added to 10 ml of sterile autoclaved LB in a universal bottle.  
The universal bottle was then capped loosely and was secured onto a 37 °C 
shaking bath at 220 rpm to incubate. The density of the competent cells was monitored. 
This was done by randomly taking out 3 cultures and the cultures were diluted 100× by 
adding 495 μl of LB broth and 5 μl of culture and mixing them by pipetting in a 
disposable cuvette.  
The culture was returned immediately to continue incubating. The 
spectrophotometer was set at a wavelength of 600 nm in ultraviolet spectrum. Before 
the sample was loaded, the spectrophotometer was “blanked” by dispensing clean and 
uncultured LB broth into the disposable cuvette. The cell density was determined by 
measuring the OD600. This step was repeated at a 15 minute interval and more 
frequently (5 minutes) as the OD600 reading approaches close to 0.5. The incubation was 
stopped when the OD600 measures as 0.5. This was because, the cell culture at this stage 
was in the log phase and the cell at this phase was most optimal for competent cell 
preparation. The competent cell culture was then transferred into sterile 15 ml falcon 
tubes using aseptic technique. The tubes containing the cells were then left on ice for 15 
to 30 minutes. The tubes of cells were then centrifuge at 3000 rpm at 4 °C for                
5 minutes. The supernatant was discarded and 5000 μl of RF1 (every 100 ml contains 
1.20 g RbCl2, 0.99 g MnCl2.4H2O, 0.30 g KoAC, 0.15 g CaCl2.4H2O, 15 ml glycerol 
(AnalaR, England), sterile distilled water added and had the pH adjusted to 5.8, and the 
solution was filter sterilised)  was added to the pellet and was resuspended (on ice).  
The tubes were then left on ice for 20 minutes. The tubes were once again 
centrifuged at 3000 rpm at 4 °C for 15 minutes. The supernatant was discarded and was 
resuspended in RF2 (every 100 ml contains 0.21 g MOPS, 0.12 g RbCl2, 1.10 g 
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CaCl2.4H2O, 15.0 ml glycerol and sterile distilled water and had the pH adjusted to 6.8, 
and the solution filter sterilised). The amount of RF2 added varies from 100 μl to 400 μl 
depending on the pellet size. The prepared competent cell was then aliquot into sterile 
1.5 ml microcentrifuge. The microcentrifuge was then dipped into liquid nitrogen and 
then stored at -80°C. 
 
2.4.2 LB plates with ampicillin / IPTG / X-Gal 
LB agar (Pronadisa , Madrid-Spain ) plates with (100 μg/ml) ampicillin (Sigma, 
USA), 0.5 mM IPTG, and 80 μg/ml X- gal were prepared prior to the transformation 
day as it requires time for autoclaving and for the agar to set. Prior to transformation 
conducted the LB plates were dried in 37ºC incubator. This was to ease the plating of 
the transformed cells and to avoid contamination. 
 
2.4.3 LB Broth Preparation (Pronadisa, Madrid-Spain) 
20 g of the dehydrated medium was dissolved in 900 ml of distilled water and 
then it was dissolved with frequent agitation until completely dissolved. Final volume 
was adjusted to 1000 ml. It was then sterilized at 121°C for 15 minutes. 
 
2.4.4 Ligation reaction with pGEM®-T vectors 
a pGEM ®-T vector (Promega, USA) was used in cloning. The pGEM ®-T 
vector DNA tube was briefly centrifuged to collect the contents in the bottom of the 
tube. The ligation reaction was set up in 0.5 ml microcentrifuge tubes as it is known to 
have low DNA binding capacity. The 2× rapid ligation buffer was thawed on ice and 
vortexed prior to each use. The 10 μl ligation reaction was set up containing   5.0 µl 2× 
Rapid ligation Buffer, 1.0 µl pGEM®-T vectors (50 ng), 3 µl purified PCR product and 
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1.0 µl T4 DNA Ligase (3 Weiss unit/ µl). The reactions were mixed by pipetting and 
incubated at 4ºC overnight for the maximum number of transformants. 
 
2.4.5 Transformation into JM109 competent cells  
The tubes containing ligation product were centrifuged to collect the content at 
the bottom of the tube. 2 µl of each ligation reaction was added to a sterile 1.5 ml 
microcentrifuge on ice. Tubes of frozen JM109 competent cells were removed from -
80ºC storage and were placed on an ice bath until just thawed. The cells were mixed by 
flicking the tube gently. A 100 µl of cells were carefully transferred into each of the   
1.5 ml microcentrifuge tubes containing the ligation product. The tubes were flicked 
gently to mix the cells and the ligation product.  
The tubes were then place on an ice bath for 20 minutes. The cells were then 
heat-shocked for 45 seconds in a water bath at exactly 42ºC without shaking. The tubes 
were immediately returned to ice for 2 minutes. 900 µl room temperature LB broth was 
added to the tubes containing cells transformed with ligation reaction. It was then 
incubated for one and a half hour at 37ºC in rotating hybridization oven. The tubes were 
then centrifuged at 1000 × g for 10 minutes to pellet the cells. 800 µl of the supernatant 
was discarded and the pellet was resuspended with the remaining supernatant. A 100 µl 
of the transformed cells were plated on the LB agar plates using a spreader. The plates 
were then incubated overnight (16 hours) at 37 ºC incubator. 
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2.4.6 Recombinant Colonies Screening 
 
When the desired PSMA fragments was inserted into the LacZ’ gene of M13 
cloning vector, it inactivates the β-galactosidase synthesis causing the formation of 
white colonies on the LB/ Ampicillin/ IPTG/ X-gal plates after overnight incubation. 
Blue colonies were formed when there is no inserts in this gene. 
 Under a sterile condition using aseptic technique, white colonies which are 
represented by one cell each was picked to build library on a new LB/ Ampicillin/ 
IPTG/ X- gal plates. The library later was incubated at 37°C overnight (16 hours). 
While constructing the library, the loop that is used to pick up the colony is immersed in 
50 μl of autoclaved distilled water in a 0.5 ml microcentrifuge tube before being flame 
sterilised. Tubes containing the transformed colonies were boiled at 99°C for               
10 minutes to lyse the cells. This was then proceeded by colony PCR using M13 
forward and reverse primers. The PCR product was then analysed by mixing 1 volume 
of 6× loading dye and 5 volumes of purified DNA and electrophoresis in a 1% stained 
agarose gel. 
 
 
2.5 Isolation of Plasmids 
A positive screened colony (with correct insert) was selected from the library 
plate and cultured in 10 ml sterile LB broth containing 50 μg/ml ampicillin (Sigma, 
USA) in a universal bottle. The universal bottle was capped loosely and was left 
incubating in a shaking (220 rpm) waterbath at 37 °C overnight (16 hours) to increase 
the transformed cells quantity for plasmid extraction. The following steps were carried 
out in sterile condition with aseptic techniques. 150 µl of 100% glycerol (AnalaR, 
England), was pipetted into each 1.5 ml microcentrifuge tube. Then, 850 μl of overnight 
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culture was added into the microcentrifuge tubes contain the culture and glycerol 
(AnalaR, England) were then mixed before being kept at -80 °C for future usage. 
The remaining overnight culture was poured into 15 ml falcon tubes and was 
centrifuged at 6000 rpm for 15 minutes at room temperature. Then, the supernatant was 
discarded and the bacterial pellet was resuspended using 200 μl ice cold Solution I     
(50 mM glucose, 10 mM EDTA, 25 mM Tris Cl) by pulse vortexing. The suspended 
pellet was then transferred into a new 1.5 ml microcentrifuge tube and 200 μl of freshly 
prepared Solution II (0.2 N NaCl, 1% SDS) was added. The sample was then mixed by 
gently inverting and was left to stand in room temperature for 4 minutes.  200 µl of ice 
cold Solution III (3 M KoAc, 11.5% glacial acetic acid) was added. The sample was 
mixed by gentle inversion and was incubated on ice for 15 minutes. The sample was 
then centrifuged at 13000 rpm for 10 minutes. The supernatant was then transferred into 
sterile 1.5 ml microcentrifuge tubes, and 3 μl of RNase (50mg/ml) (Sigma-Aldrich, 
USA) was then added. This was subsequently incubated in a water bath for an hour at 
37 °C. 
 After incubating, 600 μl of ice cold phenol (Pierce, USA) was added. It was then 
vortexed followed by centrifuging at 13000 rpm for 5 minutes. The upper layer of 
supernatant was transferred to a new 1.5 ml microcentrifuge tube. The supernatant was 
then added with 600 μl of chloroform (Merk, Germany). It was then vortexed and 
centrifuged at 13000 rpm for 5 minutes. 
 The upper layer of supernatant was transferred to a new 1.5 ml microcentrifuge 
tube. Then 0.1 volume of 5 M sodium chloride was then added followed by 2.5 volume 
of ice cold isopropanol (Merck, Germany).  It was then left to incubate on ice for         
20 minutes to collect precipitate. The sample was then centrifuged at 13000 rpm for     
15 minutes and the supernatant was discarded.  
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1 ml of ice cold 70% ethanol was added. It was then centrifuged at 13000 rpm 
for 5 minutes. The supernatant was then discarded. The pellet formed was pure DNA 
and was dried in speed vacuum for 5 minutes. Lastly, 50 μl of autoclaved distilled water 
was added and the pellet was left in 4°C overnight for the pellet to dissolve. The 
dissolved pellet was subsequently quantified through spectrophotometric method to 
identify the purity and the quantity of the isolated plasmid. 
 
2.5.1 Plasmid digestion with Sfi1 and Not1 
To carry out the cloning of the desired PSMA fragments into plasmid vectors, 
both of them need to be modified to make integration possible. The plasmid and the 
PSAM fragments were subjected to RE digestion to generate identical cohesive or 
sticky ends. In this case, the inserted DNA and plasmids were cleaved with Sfi1 and 
Not1 restriction enzymes at the Sfi1 /Not1 cleave sites. 
Firstly, concentrations of DNA samples were determined using spectrophotometer 
(Eppendorf, USA). Later, based on OD reading a master mix was prepared. 1X Tango 
buffer (Fermentas, Canada), 1 U of Sfi1 restriction endonuclease (Promega, USA),   1 U 
of  Not1 restriction endonuclease (Fermentas, Canada), 100 ng DNA samples, and 
adequate sterile distilled water, were mixed together and placed in 0.5 ml tubes and left 
in 37°C waterbath for 3 hours.  Heat inactivated used for 10 minutes at 99°C. Small 
aliquot of digested plasmid was checked by agarose gel electrophoresis to check 
complete digestion. The digested plasmid Stored at -20°C. 
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2.5.2 Plasmid purification 
After vector was completely digested, phenol/chloroform washing step was 
used, the solution was centrifuged to pellet DNA. 5M NaCl/ice cold isopropanol were 
added, and the pellet washed with 70% ethanol, air-dried and resuspended in 30 μl 
sterile distilled water. Incubated overnight at 4°C then stored at -20°C. Plasmids were 
checked by restriction and electrophoretic analysis, and then purified plasmids were sent 
for sequence analysis (Applied Biosystems, Japan). 
 
2.6 Cloning with pPICZαA vector 
2.6.1 Ligation reaction with pPICZαA vector 
Ligation reaction involved a combination of 2X ligation buffer, DNA inserts and 
plasmid vectors, T4 DNA ligase enzyme (Promega, USA) and adequate volume of 
sterile distilled water. The mixture was prepared with consideration of the insert-vector 
ratio (3:1). The components were aliquoted in 0.5 ml tubes, then mixed by pipetting and 
incubated at 4°C overnight. After ligation, the vectors have to be transformed into host 
cells. 
 
2.6.2 Preparation of low salt Luria Bertani (LSLB) medium 
The LSLB mediums were prepared in two forms, agar plates and broth. For 
LSLB agar plate preparation, 2% of peptone (Pronadisa, Canada), 3% of agar 
(Amresco, Canada), 1% of NaCl (Promega, USA) and 1% of yeast extract (Pronadisa, 
Canada), were added before stirred with 190 ml of sterile distilled water using a stirrer 
(LMS, Japan). 
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The pH of the solution was adjusted to 7.5 using a pH meter (Sartorius, China) 
and the volume was brought up to 200 ml, the solution was then autocalved for 15 
minutes at 121ºC. The autoclaved broth was cooled down with running tap water until 
temperature was around 55ºC. Next, 25 μg/ml of zeocin (Invitrogen, USA) was added to 
the broth before being poured into labeled clean petri-dishes. The plates were left at 
room temperature to solidify, and kept in 4ºC for maximum three months. 
For LSLB broth preparation, 1% of peptone was mixed with 0.5% of yeast 
extract and NaCl in 90 ml of sterile distilled water. PH was adjusted to 7.5 and total 
volume was topped up to 100 ml. Broth were then aliquoted, 10 ml into each universal 
bottle and autocalved. 
 
2.6.3 Transformations into Top10 cells 
Prior to transformation, the host cells have to be prepared with the same 
procedure, which mentioned in (section 2.4.1). 100 μl of the frozen stocks of E. coli 
Top10 cells in each tube were thawed on ice for 5 minutes.  Then, 5 μl of ligation 
reaction was transferred into each tube (s) containing competent cells, mixed gently by 
flicking and incubated on ice for 30 minutes. After that, the mixtures were heat shocked 
at 42°C for 90 seconds and immediately chilled on ice for 5 minutes. 900 μl room 
temperature LSLB broth (Appendix A) was added to the mixture and incubated for    
1.5 hours at 37°C with shaking (~250 rpm). After transformation, 100 μl of each 
transformation mix were spread on the LSLB medium containing zeocin and incubated 
overnight (16-24 hours) at 37°C. Plates were placed at 4°C for short term storage. 
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2.6.4 Recombinant colonies screening 
Cells that were successfully transformed will be conferred resistance to zeocin 
antibiotic present in the medium. Using sterilized looped wire, the colonies were picked 
randomly since all colonies were white. Tip touched onto library plate drawn with 6×6 
grids while the rest were mixed in 30-50 μl of sterile distilled water. The tubes 
containing the transformed colonies were heated at 99°C for 10 minutes to lyse the cells 
before proceeding to colony PCR. Meanwhile, the library plates were incubated at 37°C 
overnight. 
 
2.6.5 Colony PCR 
This PCR method was employed for selection of colonies that were successfully 
transformed with vectors containing inserted DNA. Inserted sequences were amplified 
with a thermocycler (as previously mentioned). Clones providing an amplicon of correct 
size were identified by agarose gel electrophoresis. Right clones were picked up, and 
grown in 10 ml LSLB broth containing 2.5 μl zeocin, and then incubated overnight at 
37°C. Cells were grown and recombinant product was isolated by using convential 
procedure (section 2.4.7) and linearized by restriction endonuclease Sac1 (Fermentas, 
Canada). 
 
2.7 Transformation into Pichia pastoris 
Recombinant plasmid DNA was first linearized by restriction endonuclease Sac1 
(Fermentas, Canada) and then transformed into P. pastoris strain X33 (Prondisa, 
Canada) by using EasyComp Transformation kit (Invitrogen, USA), following 
manufacturer’s instructions.  
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3. Results 
 In order to obtain a full length sequence of the PSMA gene for cloning and 
expression of the protein two approaches were used. One of the approaches is by 
overlapping the three fragments from the PCR product. The other approach was by 
cloning the gene fragments into a vector system (pGEM-T vector) and then overlapped 
them from the isolated plasmids. 
 
3.1 Construction of PSMA gene from PCR product 
 
3.1.1. Construction of G1  
The G1 fragment of PSMA gene is further divided into six sub fragments namely 
fragment a, b, c, d, e, and f. All the fragments were obtained from the previous students 
with the exception of fragment d. Fragment d  was amplified  by using two steps PCR 
with 3’oligo’s (45bp), and  primers  PSMA4F as forward primer and PSMA4R in 
second step (Appendix b). 
 
 
 
 
 
 
 
PSMA G1 Fragment 
Figure 3.1 PSMA G1 fragment and its six subfragments 
 
Fragment 
a 
Fragment 
b 
Fragment 
c 
Fragment 
d 
Fragment 
e 
Fragment 
f 
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PCR amplification was carried out to amplify the desired fragments and sub 
fragments which was subsequently needed for the construction of the PSMA gene. In 
figure 3.1, the fragment G1-d was successfully amplified using two steps PCR and the 
band produced was sufficiently bright at the desired size of 101bp. 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Two steps PCR for G1-d fragment of the PSMA gene. Lane L is the 100bp 
ladder (Seegene, Korea), lane N is the negative control, and lane 1, 2, and 3 
is the amplification product of the two steps PCR for fragment G1-d of the 
PSMA gene. 
 
As the gel picture shows there are traces of unspecific bands in this PCR product 
as well as primer dimers. In order to proceed with the construction of the PSMA gene 
only the specific fragment is needed. Hence the product here in figure 3.1 was 
subsequently purified using the gel extraction method to eliminate the unspecific band 
which are present in the gel.  
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As only the desired fragment was needed, purification of the PCR sample was 
required and to eliminate the unspecific bands and primer dimers, gel extraction was 
carried out. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Gel extraction product for the G1-d fragment of the PSMA gene showed 
only a single band at the desired size 101bp with high intensity. L is the 
100bp ladder (Seegene, Korea), and lane 1 is the purified product of the G1-
d fragment of the PSMA gene. 
 
 Figure 3.2 illustrate the sample purified by means of gel extraction which shows 
only a single band with the desired size of 101bp in high intensity. Other undesired 
bands and dimers were eliminated from the PCR product with this procedure as only the 
desired fragment was excised to be purified. 
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After obtaining the six sub-fragments of G1, a two-steps PCR was carried out to 
construct G1. In the first step, all six fragments were overlapped. In the second step, G1 
was amplified using G1 specific primer Sfi PSMA F as the forward primer & PSMA 
961R as the reverse primer.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Two-steps PCR for the construction of G1 fragment of the PSMA gene. 
Lane L is the 100bp ladder (Seegene, Korea), lane N is the negative control, 
and Lane 1, 2 and 3 is the G1 fragment constructed. 
 
All the six G1 sub fragments were successfully overlapped and the G1 fragment 
was successfully amplified at the desired size of 733bp as illustrated in figure 3.3. 
However, unspecific bands were also present in the PCR product. In order to construct 
the PSMA gene, G1, G2, and G3 fragment need to be overlapped and only the specific 
fragment of G1 is needed hence gel extraction need to be carried out. 
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3.1.2 Amplification of PSMA G2 
 The results shown on figure 3.4 is a gel picture for the PCR amplification of the 
G2 fragment of the PSMA gene using specific primers PSMA 961 F as forward primer 
and PSMA 1741 R as reverse primer. The G2 fragment was successfully amplified and 
this produces band with the expected size of 723 bp. 
 
 
 
  
 
 
 
 
 
 
Figure 3.4: PCR amplification of the G2 fragment of the PSMA gene using Pfu 
polymerase. Lane L is the 100bp ladder (Seegene, Korea), Lane 1, 2, 3, 4 
and 5 is the G2 fragment amplified which were amplified at the expected 
size, and lane N is the negative control. 
 
 Unspecific bands were also present in these PCR products and hence gel 
extraction was needed to be carried out to obtain the pure G2 fragment for subsequent 
procedure of overlapping the fragments PSMA gene. 
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3.1.3 Amplification of PSMA G3 
The results illustrated on figure 3.5 is a gel picture for the PCR amplification of 
the G3 fragment of the PSMA gene using specific primers PSMA 800 F as forward 
primer and PSMA facXa-Not1R as reverse primer with the expected size 790 bp. The 
G3 fragment was successfully amplified and this produces band with the expected size 
of 790 bp. 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: PCR amplification of the G3 fragment of the PSMA gene using Pfu 
polymerase. Lane L is the 100bp ladder (Seegene, Korea), lane 1, 2, and 3 is 
the G3 fragment amplified which were amplified at the expected size, and 
lane N is the negative control. 
 
 
Unspecific bands were also present in these PCR products and hence gel 
extraction was needed to be carried out to obtain the pure G3 fragment for subsequent 
procedure of overlapping the fragments PSMA gene. 
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3.1.4 Purification of PSMA gene fragments 
The result shown on figure 3.6 is a gel picture for PCR PSMA gene fragments 
(G1, G2 and G3) before purification (figure 3.6a) and product of the  purified PSMA 
gene fragments (G1, G2 and G3) (figure 3.6b)  by gel extraction, using QIAquick Gel 
Extraction kit (Qiagen, USA) according to the manufacturer's instructions.  
 
 
 
 
 
 
 
        
 
(a)                                                       (b) 
                                             
Figure 3.6: (a) PSMA gene fragments before gel extraction. (b) PSMA gene fragments 
after gel extraction. Lane L is the 100bp ladder (Seegene, Korea), lane 1 is 
G1 fragment, lane 2 is G2 fragment and lane 3 is G3 fragment. 
 
After gel extraction, the bands obtained were significantly fainter and the band 
sizes obtained were smaller than the initial size of ~700bp. So, to overcome this 
problem the extracted fragments were heated up at 80º C for five minutes and then 
cooled down to room temperature. 
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3.1.5 Overlap extension from PCR product 
The combination of the three fragments should be joined as following table: 
Table 3.1: PSMA fragment combinations 
Overlap extension PCR Fragment 1 Fragment 2 Expected size 
1
st
 PSMA G1 PSMA G2 1456 bp 
2
nd
 PSMA G1-G2 PSMA G3 2246 bp 
 
 
Figure 3.7 is the gel picture showing the overlapped extension from the 
fragment G1 and G2.  The overlapped fragment was amplified using the primers         
Sfi PSMA –F as forward primer and Psma 1741 R as reverse primer with expected size 
1456bp. The overlapped fragments shows smear after running in the gel and no clear 
band obtained. 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Overlap extension of G1 and G2 fragments. Lane L is the 100bp ladder 
(Seegene, Korea). Lane 1 to 4 is the result of the overlapped extension of 
G1-G2, and lane N is the negative control. 
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3.1.6 PCR optimization to amplify G1-G2 after overlapping 
 
 With no clear band obtained, a temperature gradient PCR was carried out to 
further optimize the amplification of G1-G2.  Six different temperatures were chosen 
and the temperature ranged from 45ºC to 65ºC. 
 The best temperature for the amplification is 50.5 ºC in lane 3 as shown in 
figure 3.8; however, there is still no clear bands obtained at the expected size ~1456 bp. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8:  A temperature gradient PCR for the amplification of overlapped G1-G2. 
Lane L is the 100bp ladder (Seegene, Korea), Lane 1 is PCR at 45.0 ºC, lane 
2 at 48.2 ºC, lane 3 at 50.5 ºC, lane 4 at 56.7ºC, lane 5 at 61.8 ºC and lane 6 
at 65.0 ºC. 
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 As no clear band was observed even at the optimum temperature of 50.5 ºC, a 
serial dilution was carried out to dilute the template for PCR. PCR product from lane 3 
(50.5 ºC) figure 3.8 was used as the template. 
 
  
 Even with serial dilution of the template for PCR, no improvement was 
obtained as shown in figure 3.9. All amplification from different dilutions only 
produces smears and no specific band was produced. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Serial dilution of template for G1-G2 PCR. Lane L is the 100bp ladder 
(Seegene, Korea). Lane 1 is G1-G2 PCR product as template, lane 2 is 10 × 
dilutions of the template, lane 3 is 100× dilutions of the template, lane 4 is 
1000× dilutions of the template and  lane N is negative control. 
 
Since the approach of overlapping with PCR products not being successful, 
overlapping using plasmid from cloned fragments would be carried out as an alternative 
option to obtain the complete PSMA gene. 
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3.2. Cloning 
 3.2.1Cloning of PSMA G1, G2and G3 
Cloning method was used for each PSMA fragments to get high quantity of the 
fragments. Two approaches were applied in this project to clone the fragments with 
pGEM-T vector and transformed into JM109 competent cells. First approach was 
cloning of each fragment separately. Second approach was cloning of overlapped 
fragments that are PSMA G1-G2, PSMA G2-G3 & PSMA G1-G2-G3. After that, all 
these are to be used in construction PSMA gene. 
 G1, G2 and G3 fragments was amplified individually using Taq polymerase and 
the PCR product was subsequently purified and used for cloning. 
                    
 
 
Figure 3.10:  Gel extraction of amplified PCR product of G1, G2 and G3. Lane 1 is G1, 
lane 2 is G2 and lane 3 is G3. Lane L1 is 100bp ladder (Seegene, Korea). 
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Colony PCR was performed on colonies, which was transformed with pGEM-T 
vector ligated with G1, G2, and G3 fragment to select a colony containing the right 
insert. The expected size is approximately ~900bp for the colony PCR using M13F and 
M13R for all the fragments cloned. 
 
 
 
Figure 3.11: Colony PCR of PSMA G1, G2 and G3. Lane 1 to 8 and 19 to 23 is clones 
for PSMA G1 (~733+(265bp size of M13F/R primers). Lane 9 to 11 is 
clones for PSMA G2 (~723+265bp). Lane 12 to 18 is clones for PSMA G3 
(~790+265bp). Lane L is 100bp ladder (Seegene, Korea), and lane N is the 
negative control. 
 
The clones of PSMA G1, G2, and G3 with the right fragment size~900bp were 
then selected for plasmid isolation. Based on figure 3.11, colonies (G1) are 3, 5 and 21; 
(G2) is 11; and (G3) is 14 were selected and subsequently used for plasmid isolation. 
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 Clones containing the right expected size fragments were cultured and the 
plasmids isolated, show in figure 3.12.  
 
  
 
 
 
 
 
 
 
Figure 3.12: Plasmid Isolated for clones of PSMA G1, G2 & G3. Lane L is 100bp 
(Seegene, Korea), lane 1 is PSMA G1 fragment plasmid isolated from 
cloned 3, lane 2 is PSMA G1 fragment plasmid isolated from cloned 5, lane 
3 is PSMA G2 fragment plasmid isolated from cloned 11, lane 4 is PSMA 
G3 fragment plasmid isolated from cloned 14 and lane 5 is PSMA G1 
fragment plasmid isolated from cloned 21. Each one has two bands except 
G3 (14) no band appear due to failed in plasmid isolation or low 
concentration of the plasmid isolated. 
 
 The plasmid isolation step was successfully carried out as plasmids were 
obtained from most of the clones except one. 
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Subsequently, the PCR of the specific fragment was carried out to detect the 
presence of the desire insert. This is to verify that the desired fragment was cloned and 
not other DNA fragment of similar size. 
 
 
  
Figure 3.13: PCR product of amplifying PSMA G1, G2 & G3 from the diluted plasmid. 
Lane L is 100bp ladder (Seegene, Korea), Lanes 1, 2 and 5 is G1fragments 
amplified from cloned 3, 5 and 21 respectively G1 (~733+265bp expected 
size of specific primers). Lane 3 is fragment G2 amplified from cloned 11 
(~723+265bp). Lane 4 is fragment G3 amplified from cloned 14 
(~790+265bp). 
. 
 
Based on the fragment specific screening, plasmid from colonies 1 (lane1), 5 
(lane2), 11 (lane 3) and 14 (lane 4) were used for sequencing. 
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3.2.2 Sequencing result of PSMA G1, PSMA G2 and PSMA G3 
 The sequencing results for the PSMA G1, result shows that there is a deletion in 
both sample of PSMA G1 that is clone a3 and a5 (figure 3.14a and 3.14b)  
  
Figure 3.14: G1 sequencing results (a) showed the deletion of G nucleotide at 459 in G1 
sequencing in sample number 3 (b) showed the deletion of G nucleotide at 
845 in G1 sequence in sample number 5. Due to the deletion in G1 
sequence, cloning of the PSMAG1 fragment was repeated. 
 
The fragment for PSMA G2 (clone 11) and G3 (clone 14) were successfully 
cloned and the complete sequence of the fragment were obtained                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
(Appendix C). Based on the sequencing result cloning of G1 have to be repeated.    
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3.2.3 Re-cloning of G1 Fragment 
In figure 3.15, colonies that were selected were screened by carrying out colony 
PCR using M13F and M13R primers.  Lanes 1, 2, 3, 4 and 5 shows faint bands of 900 
bp, which was the expected size, while lane 7 and 9 are colonies with wrong inserts. 
 
 
 
 
 
 
 
 
Figure 3.15: Colony PCR amplifications using M13F and M13R primers. Lane 1 to 9 
(a1- a9), are all colonies picked from cloning of the fragment G1, lane N is 
negative control and lane L is 100bp ladder (Seegene, Korea). 
 
 
Three colonies (a1, a2 and a4) were selected from the colony PCR and proceed for 
plasmid isolation process.  
 
 
 
 
 
 
 
 
Figure 3.16: Plasmid isolated from colonies of G1. Lane 1 is plasmid from colony a4, 
lane 2 is plasmid from colony a2, lane 3 is plasmid from colony a1 and lane 
L is the 100 bp ladder (Seegene, Korea). 
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PCR confirmation was carried out on the plasmid isolated using G1 specific 
primers (Sfi PSMA F & PSMA 961 R) and the bands with expected size were obtained 
as illustrated in figure 3.17.  Correct amplification size of the G1 fragment indicates 
correct inserted fragment and hence sequencing of the plasmid could carried out. 
 
 
 
 
 
 
 
  
 
 
Figure 3.17: PCR verification of the plasmid isolated from colonies of G1: Lane L is the 
100bp ladder (Seegene, Korea), lane 1 is a4 PCR of plasmid isolated 
colony, lane 2 is a2 PCR of plasmid isolated colony, and lane 3 is a1 PCR of 
plasmid isolated colony. 
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Figure 3.18: Nucleotide sequences based on sequencing results of (a) G1-a1, (b) G1- a2, 
(c) G1-a4. The figures showed the replaced nucleotide and the repairing area according 
to the amino acid codon. 
From the analyses of the sequencing results for all three sample of G1 (a1, a2 & a4), 
plasmid isolation of (G1_a4) showed the minimum mutation which can be repaired and 
does not affect the amino acid of the protein. Hence, sample (G1_a4) clone was used for 
subsequent work. 
(b) 
(c) 
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3.2.4 Overlapping of PSMA G1, G2 and G3 fragments from plasmid isolation 
product 
               Overlap extension PCR was conducted in three different combinations of 
template. All the overlapping combination and the expected size showed in the 
following table. 
Table 3.2: PSMA G1, G2 and G3 fragments combination for overlapping PCR 
combination Fragment 1 Fragment2 Fragment 3 Expected size 
1 G1 G2 - 1456bp 
2 G2 G3 - 1513bp 
3 G1 G2 G3 2246bp 
 
 
  
 
Figure 3.19: Two Steps PCR were done; both steps were carried out with Pfu 
polymerase enzyme. Lane L is 1kb ladder (Promega, USA), Lane 1 to 4 is 
G1-G2 fragment (1456bp), lane 5 to 8 is G2-G3 fragment (1513bp), lane 9 
to 12 is G1-G2-G3 fragment (2232bp) and lane N is the negative control. 
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Figure 3.20: Two steps PCR were done, 1
st
 step overlapping with Pfu polymerase 
enzyme and 2
nd
 step amplifying with Taq polymerase enzyme. Lanes L1 
and L2 is 1kb ladder (Promega, USA), Lane 1 to 3 is G1-G2 fragment 
(1456bp), lane 4 to 6 is G2-G3 fragment (1513bp), lane 7 to 9 is G1-G2-
G3 fragment (2232bp), and lane N is the negative control. 
 
In comparison of using different enzymes to amplify the fragments after 
overlapping it is shown that Taq polymerase (figure 3.20) is more efficient as compared 
to Pfu polymerase (figure 3.19). Amplification using Pfu polymerase shown no bands at 
the desired size whilst amplification using Taq polymerase successfully amplified the 
desired bands although the intensity could range from faint to intense bands. 
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Figure 3.21: Gel extraction of PSMA G1-2, PSMA G2-3 & PSMA G1-2-3. Lane L is 
1kb ladder (Promega, USA), lane 1 is PSMAG1-2, lane 2 is PSMA G2-3 
and lane 3 is PSMA G 1-2-3. 
 
 
3.2.5 Sequencing of the overlapped fragments 
 All fragments after purification only had shown faint bands due to much of it 
being lost in the purification process. The purified fragments PSMA G1-G2, PSMA G2-
G3 & PSMA G1-G2-G3 were then cloned in JM109 cells but did not produce 
significant results as the sequencing results indicated the presence of partially inserted 
sequence and the sequence with mutation (data not shown). 
Since this approach yielded no results, another attempt was done by amplifying 
the G1 fragment from the isolated plasmid and amplify G2-G3 overlapped fragment 
using the isolated plasmid and then overlapping both of these amplified products. 
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3.2.6 PCR optimization to amplify G1 
In the PCR optimization of G1, the enzyme type and quantity were the 
parameters, which were manipulated at this stage. Two types of the enzymes were used, 
namely Taq polymerase and Pfu polymerase, to amplify PSMA G1 fragment. The 
amplified product using Pfu polymerase was used in overlapping while which amplified 
with Taq was used in cloning.  
 
 
 
 
 
Figure 3.22: PCR amplification of G1using plasmid (colony a4) as template with one unit of Pfu 
polymerase enzyme and one unit of Taq polymerase enzyme. Lane 1 to 3 is the G1 
fragment amplified with one unit of Pfu polymerase enzyme, lane 4 to 6 are G1 fragment 
amplified with one unit of Taq polymerase enzyme, lane N is the negative control and 
lane L is 100bp ladder (Seegene, Korea). 
 
 
 
 
 
. 
Figure 3.23: PCR amplification of G1using plasmid (colony a4) as template with 1.5 
unit of Pfu polymerase enzyme. 
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 It is shown that Pfu polymerase could only amplify using a much higher 
concentration as shown in figure 3.23, using one unit of Pfu polymerase did not yield 
any bands (figure 3.22) while by using 1.5 units of Pfu polymerase the desired fragment 
could be amplified. 
3.2.7 PCR optimization of overlapping G2-G3 
 PCR optimization was carried out to obtain optimal amplification of G2-G3 
fragment after the overlapping PSMA G2 and G3, which carried out using plasmid of 
G2 and G3 clones. The parameter, which manipulated was the concentration of the 
enzyme for each PCR reaction. 
 
 
 
 
 
 
(a)                                                            (b) 
Figure 3.24: (a): Overlap PCR of PSMA G2 and G3 fragments using one unit of Taq 
polymerase enzyme. Lane L is 1kb ladder (Promega, USA), lane N is 
the negative control and lane 1 to 3 is the Overlap PCR amplification 
 
                      (b):  Overlap PCR of PSMA G2 and G3 fragments using two units of Taq 
polymerase enzyme. Lane L is 1kb ladder (Promega, USA), lane N 
is the negative control and lane 1 to 2 is the Overlap PCR 
amplification. 
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(a)                                                                  (b) 
Figure 3.25: Overlap PCR of PSMA G2 and G3 fragments. Amplify PCR done by using 
2 units of Taq for each PCR  reaction .(a) The PCR run in PCR machine 
(Peltier Thermal Cycler 200 MJ Research.(b) The PCR run in PCR machine 
(PCR system 2400). 
 
In figure 3.25, it is clearly shown that different PCR machine shows different 
efficiency. Under same parameters and same reagents and template, Peltier Thermal 
Cycler 200 MJ Research could not amplify the fragments whilst PCR system 2400 
could. 
Overlapping PSMA G2-G3 from different template source was one of the 
parameter, which manipulated in order to obtain the optimum amplification of the 
overlapped fragment of PSMA G2-G3. 2units of Taq polymerase enzyme was used in 
the PCR amplification using of two different templates, namely PCR product of G2 and 
G3, and the plasmids from clones G2 and G3. 
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As shown in figure 3.26, PCR product as the template for overlapping did not 
produce a clear band but instead a smear was produced while in comparison to the 
isolated plasmid as a template, clear band was produced at the desired size. 
 
 
Figure 3.26: Overlap PCR of PSMA G2 and G3 fragments from different DNA 
templates. Lane 1 to 4 are overlapped PCR of G2 and G3 fragments using 
PCR product of G2 and G3, lane 5 to 8 are overlapped PCR of G2 and G3 
fragments using isolated plasmid from cloning of G2 and G3 fragments. 
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Gel extraction for overlapped PCR of G1 and G2-3 fragments were done using 
QIAquick® Gel Extraction Kit (Qiagen) following protocol.  
 
 
 
 
 
 
 
 
 
Figure 3.27: Gel extraction of the PCR of G1 fragment from a4 colony plasmids. Lane 
L is the 100bp ladder (Seegene, Korea) and   Lane 1 is the purified G1 
fragment.  
 
 
 
 
 
 
 
 
 
 
Figure 3.28: Gel extraction of the PCR of G2-G3 fragment. Lane L is the 1kb ladder 
(Promega, USA), and lane 1 is the purified G2-G3 fragment. 
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3.2.8 Overlapping PSMA G2-G3 with G1: 
 
 
 
 
 
 
 
 
 
 
Figure 3.29: Overlap PCR of PSMA G2-G3 with PSMA G1. Lane L is 1kb ladder 
(Promega, USA), lane 1 and 2 is PSMA G1-G2-G3, and lane N is the 
negative control. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.30: PCR optimization of PSMA G1-G2-G3 sample through annealing 
temperature ranging between 45ºC to 63.4ºC. Lane 1 at 45.0ºC, lane 2 at 
48.2ºC, lane 3 at 50.5ºC, lane 4 at 56.7ºC, lane 5 at 59.6ºC and lane 6 at 
63.4ºC and lane L is 1kb ladder (Promega, USA). 
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 Although optimizing of the annealing temperature was carried out, it did not 
produce significant difference at different annealing temperature as all products formed 
from different annealing temperature was the same and have a smearing effect. 
 Hence, the product was then purified using gel extraction method and a faint 
band was produced as shown in figure 3.31. 
 
 
 
Figure 3.31:  Gel extraction of the amplified PSMA G1-G2-G3. Lane L is 1kb ladder 
(Promega, USA), lane 1 is PSMA G1-G2-G3. 
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 The purified product was subsequently cloned using pGEM®-T vectors to 
amplify the fragment. 
 
 
Figure 3.32: Colony PCR of PSMA G1-2-3 by using M13 forward and reverse primers. 
Colonies containing the insert were successfully identified through colony 
PCR. Lanes 2, 3, 9 and 13 showed bands at the expected size ~2500 bp 
(2246bp+ 256bp size of specific primers) due to colony having the correct 
insert. Lane L is 1kb ladder (Promega USA); lane N is the negative control. 
   
 
Figure 3.33: Plasmid isolation of PSMA G1-2-3 of the samples 2, 3, 9 and 13. Lane L is 
1kb ladder (Promega USA). 
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 The plasmid samples were sent for sequencing, and subsequently cloned using 
pPICZαA vector to amplify the fragment after digestion with SfiI and NotI restriction 
enzymes. 
 
3.3 Plasmid digestion with Sfi1 and Not1 
 
To determine if the insert is in the correct size, the plasmid from both sides was 
digested with Sfi1 and Not1 in a total volume of 50 μl. The mixtures were incubated at 
37ºC for 3 hours. Results of digestion revealing approximately 2246bp can be seen in 
figure 3.34. Digested and purified plasmids were analyzed by 1% agarose gel 
electrophoresis and sent for sequencing. 
 
 
Figure 3.34: Analysis of SfiI and Not1 restriction enzymes. Double digestion of plasmid 
isolated from PSMA G123 colonies. Lane L is 1kb ladder, lane 1- 4 showed 
a restricted plasmid, indicating that digestion has occurred.  
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3.4 Colony PCR of PSMA G123 
 
Colony PCR was conducting after ligation of the restricted plasmid PSMA G123 
into digested pPICZαA vector and transformed into E. coli strain (Top10). 23 colonies 
were selected and verified by PCR. The PCR was done by using vector primers 
(Forward primer: α-factor, Reverse primer: 3’AOX). Thus the expected PCR product 
was 2246bp + 300bp (vector primer size), approximately 2500bp. results of colony PCR 
are presented in figure 3.35. 
 
 
Figure 3.35: Colony PCR: Colonies containing the insert were successfully identified 
through colony PCR. Lane L is 1kb ladder. Lane 1 to 23 showed inserted 
(3 and 6), and non-inserted colonies, which were determined according to 
exactly expected size. Lane N is a negative control (PCR reaction without 
DNA). 
 
Selected colonies, which were determined according to expected size 2500bp, were 
proceeding for plasmid isolation. 
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Figure 3.36: Plasmid isolated from colonies 3 and 6 of PSMA G123. Lane L 
is 100bp (Seegene, Korea), lane 1 is plasmid isolated from 
clone 3, lane 2 is plasmid isolated from clone 6. 
 
3.5 Linearization of PSMA G123 
The recombinant plasmid DNA was first linearized by restriction endonuclease 
Sac1, and then transformed into P.pastoris strain X33, by using EasyComp 
Transformation kit as described in manufacturer’s manual (Invitrogen, USA). 
 
 
 
 
 
 
 
 
Figure 3.37: Linearization of PSMA G123 after digestion with Sac1 Restriction 
enzyme. Lane L is 1kb ladder. Lane 1 is a result of digested plasmid, lane 
2 is undigested plasmid. 
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4. Discussion 
PSMA cDNA consists of 2.65 kilobase and a portion of the coding region from 
nucleotide 1250 to 1700 has 54% homology to the human transferrin receptor mRNA 
(Israeli RS et al., 1993). In contrast to PSA and prostatic acid phosphatase which are 
secreted proteins, the prostate specific membrane antigen is an integral membrane 
protein.  
            The PSMA (molecular weight 100,000) similarly has representation on both 
benign and neoplastic prostate cells with more intense staining seen with malignant 
cells.  Moreover, PSMA is an integral membrane protein rather a secreted protein as is 
PSA and, therefore, may be an even more appropriate vaccine component.  
The foregoing list of known antigens which are over-represented on prostate: prostatic 
acid phosphatase (PAP); prostate specific antigen (PSA); and prostate specific 
membrane antigen (PSMA) is offered for the purpose of illustration. These well known 
antigens (or the epitope bearing fragments thereof) are proteins (or peptides) and are 
useful in the vaccines of the invention. However, the invention includes any other 
antigens substantially uniquely present on the prostate gland so that prostate derived 
tissue can be distinguished from other tissue by virtue of the presence of these antigens 
(Watt et al., 1986; Lundwall and Lija, 1987). 
For antigens that are proteins or peptides, a number of options is available in 
addition to isolation and purification. In addition to genetic engineering techniques, 
peptides, and even proteins, can be prepared using standard chemical synthesis 
methods, preferably the commercially available solid-phase-based techniques. These 
techniques are well known and according to the manufacturer's instructions automated 
systems to conduct them can be purchased and employed. 
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           In addition, protein or peptide antigens may be prepared using genetic 
engineering. Procedures for the production of pure antigens from the DNA encoding the 
desired antigen are well known to those skilled in the art. Briefly, the preferred DNA is 
expressed in a suitable recombinant expression vector such as those adapted for E. coli; 
yeast, such as Saccharomyces cerevisiae or Pichia pastoris; or filamentous fungi such as 
Aspergillus nidulans (Berzofsky J & Berkower I., 1989). 
The preparation of recombinant forms of protein antigens in a variety of host 
cells results in a variety of posttranslational modifications which affect the 
immunogenicity and other pharmaceutical properties, such as pharmacokinetics, of the 
product. Accordingly, although human prostate-specific antigen (PSA) isolated from 
human tissues has been used to induce the production of antibodies for diagnostic use, 
the immunogen prepared in this way differs from the immunogen as prepared in 
nonhuman cells, such as insect cells. The post-translational modifications peculiar to the 
recombinant host result in alternations in glycosylation pattern, folding, and the like 
(Houghten R, 1985). 
The technique of recombinant expression may also be used to produce portions 
of the desired antigen rather than the entire antigen.  Whether the antigen or a suitable 
epitope is prepared synthetically or recombinantly, it may be prepared initially as a 
fusion protein containing amino acid sequence heterologous to the amino acid sequence 
of interest. Construction of such fusion proteins is common in recombinant production 
in order to stabilize the product produced in the cell. It may be unnecessary to stabilize 
the desired peptide or protein in this way, especially if it is to be secreted from the 
recombinant cell (Houghten R, 1985, Berzofsky J & Berkower I, 1989). 
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However, the fusion protein itself may be useful as an ingredient in the vaccine, 
especially if the additional heterologous amino acid sequence supplies an 
immunogenicity enhancing property on the relevant epitope. Thus, the fusion proteins 
which contain the relevant amino acid sequences may be used simply as precursors of 
the immunogen or may provide the end-product for use in the vaccine. If the fusion 
protein is intended as an intermediate, it is useful to provide a cleavage site between the 
heterologous portion and the desired epitope. Such cleavage sites include, for example, 
the target sequences for various proteolytic enzymes, or, if the epitope does not contain 
methionine, may constitute simply a methionine residue, which is cleaved by cyanogen 
bromide. Methods to provide suitable cleavage sites are well known in the art (Hruby D, 
1988). 
 The aim of this study was to clone the complete fragment of PSMA gene, but 
since it is length was about 2.5 kb and it faced difficulties in cloning.  So, in this study 
PSMA gene was divided into three parts named as G1 as the first part of the gene, G2 as 
the second part of the gene and G3 as the last part of the gene. 
It is noted that in this study, two steps PCR were used to overlap and 
amplify the expected fragments to provide a template for amplification.  To amplify G1, 
it was also divided into six sub fragments named a, b, c, d, e and f to facilitate cloning. 
All was cloned previously except d, so this sub-fragment was amplified by overlapping 
with other fragments and it later gave the complete G1. The length was 733 bp. To 
amplify G2 and G3, it was done successfully and the length was 723 bp and 790 bp 
respectively.  
As it was shown in the results, when these three fragments were applied to 
gel extraction to excise accordingly, surprisingly the excised fragments appeared in 
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shorter length. The problems was solved by heating the extracted fragment at 80º C for 
five minutes and then cooled down to room temperature.   
To find the whole PSMA gene, these three fragments were subjected to 
overlapping and amplification in two steps PCR. To overlap these three, G1-G2 were 
subjected to overlap and then were supposed to join to G3, but this step as was shown in 
the results did not give any results, so Gradient PCR was done to find the right 
annealing temperature. A concentrated and smear pattern was found at 50.5º C, whereas 
no clear band was shown in other temperatures, so this smear pattern was applied for 
dilution to overcome the problem. Unfortunately after three times dilution, no clear 
band was found. The expected length was around 1.5 kb based on the length of G1 and 
G2. 
Since amplification of G1-G2 was failed, subsequently the amplification of 
the joint G1-G2-G3 would also failed, so it seemed that this approach is not correctly 
chosen. To find the whole PSMA gene containing G1-G2-G3, each fragment was cloned 
separately into pGEM-T vector to proceed for overlapping. On the other side, it is also 
useful to clone each fragments individually to prepare a good amount of DNA for 
overlapping step.   
Therefore, amplified fragments individually applied for gel extraction and 
successfully obtained. All were cloned into pGEM-T vector individually and expected 
clones were picked for plasmid isolation. Although one of the samples showed a faint 
band (Refer to Fig3.12) in plasmid isolation step due to low resolution of agarose gel 
but the presence of inserted fragment was proved by PCR and showed a clear band at 
expected size (900bp), which means that a little amount of template would be enough 
for amplification in PCR whereas it would not be shown on agarose gel.  
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 To find the nucleotide sequence, the plasmid isolation including the 
insertion was applied to sequencing. In G1, one deletion was found in each sequenced 
sample due to Taq polymerase enzyme errors as it was shown in the results (Figure 
3.14). In G2 and G3 fragments, the successful complete sequence without any deletion 
was obtained.  To check the presence of deletion in G1, this fragment was cloned again 
into pGEM-T vector and proceeds to sequencing. Some substitution in nucleotide 
sequences were found among three samples (Figure 3.18).  Out of three sequenced G1 
samples, one with less affected mutation in amino acid sequences was chosen to 
proceed to overlapping with G2 and G3. Hopefully the mutation in G1 sequence would 
not make overlapping failed. 
To overlap these plasmid isolated fragments, two approaches were used. 
First was overlapping one fragment individually in one reaction and second was 
overlapping all three fragments in one reaction. To compare these two approaches 
theoretically, it is necessary to mention that first approach is time consuming, however, 
the second approach is complicated as there would be a competition among three 
fragments in one reaction to overlap which it affects the specificity and efficiency of the 
results. In this study both approaches were done.  
Based on first approach, G1 and G2 as well as G2 and G3 were overlapped. 
Based on second approach all three fragments were overlapped and then proceed for 
amplification using Pfu enzyme in both steps of overlapping and amplification. 
Unfortunately, it was not shown any results. It was thought that changing the enzyme to 
Taq enzyme might solve the problem, so Taq enzyme was used in both steps in 
overlapping and amplification and successfully showed the expected band            
(Figure 3.20), as well as some unspecific bands may due to contamination of template, 
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usage of unsterilized pipette, repeated usage of pipette tips, mater mix and even PCR 
reagents.  
Expected fragments were applied to gel extraction. Although they were faint 
after being extracted, but they all proceed to cloning. Unfortunately, all were failed in 
sequencing step due to the low ratio of ligation, transformation failure, and low 
numbers of clones containing overlapped fragments. 
Probability, previous trial was failed due to the low concentration of 
fragments, so the amplification of G1 as well as G2-G3 was optimized to get high 
concentration and purity. To optimize G1 amplification, one unit of Taq and one unit of 
Pfu were used to amplify the fragment. As it was shown in the results (Figure 3.22), by 
using of Taq compared to Pfu, fragment was amplified expectedly. It might be due to 
high efficiency of Taq enzyme in amplification.  It was also shown that changing the 
amount of Pfu from one unit to one unit and a half changed the result and gave the 
expected amplicon, which means that increasing the amount of enzyme will help 
amplification accordingly.  
Three optimization steps were done for G2-G3 as increasing the amount of 
enzyme, testing PCR machine and changing the template.  Using of Taq enzyme from 
one unit to two units was shown that expected fragment was being amplified when two 
units of Taq enzyme was used (Figure 3.24). This can explain that increasing the 
amount of enzyme again can lead to more product amplification.  
Testing two PCR machine surprisingly gave different results as follows 
(Figure 3.25). When PTC 200 was used for amplification, no band was amplified 
whereas with PCR system 2400 expected band was amplified. It seems that PCR 
machine itself also affects the results in such way that when they should adjust to exact 
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temperature and time, they fail. Also it was thought that PCR 200 machine fails to 
amplify the longer fragment more than 1500 bp.  
For template optimization, using of amplified fragments by PCR as a 
template failed to provide a good template for overlapping compared to cloned 
fragments in plasmid which shows that when fragments clone into vector give better 
template for overlapping and amplification. This is might be due to the amount and 
concentration of DNA as a template.     
To summarize all optimization work which was done, it is worth to mention 
that two units of Taq enzyme, PCR machine 2400 and Plasmid isolation as a template 
were ended to result.  To continue G1 overlapping with G2-G3, gel extraction was done 
successfully which was applied to overlapping. The expected band was obtained as well 
as some unspecific bands due to contamination mentioned before. To remove the 
unspecific bands, gradient PCR was done but this step apparently did not change the 
previous result, as different temperature in gradient PCR did not produce different result 
accordingly due to errors in PCR machine in adjusting the exact temperature.  However, 
the expected fragments were excised and proceed for cloning. The length of plasmid 
together with the inserted fragment was about 2500bp (figure 3.32), which was found 
and proceed for sequencing.  
To carry out the cloning into pPICZαA vector, plasmid samples were 
digested with Sfi1 and Not1 restriction enzyme from the both sides. Digested and 
purified plasmids were sent for sequencing. However, the digested plasmids were 
cloned into digested pPICZαA vector, clones were amplified using vector specific 
primer; the result shown some of the colonies at the expected size 2500bp (Figure 3.35); 
therefore the clones with the corrected fragment size was proceed for sequencing. 
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PSMA G123 fragment was then linearized by using sac1 restriction 
enzyme. Additionally, linearized DNA can be inserted in high efficiency via 
homologous recombination procedures to generate stable cell lines whilst expression 
vectors can be readily prepared that allow multiple copies of the target protein. 
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6. Conclusion 
 
In this project, partial PSMA was successfully sequenced but due to limit 
of time, it was not troubleshoot to get the complete fragment. By looking into the 
importance of PSMA, it is worth to find the complete fragment of PSMA to be able to 
be expressed in Pichia pastoris as an expressing system with more effort and time.   
To overcome this problem, it is suggested to use special Taq enzyme with 
a special technique such as LA technique which can help to amplify PSMA gene. In LA 
technique, conventional Taq polymerase mixes with a thermostable proof reading 
enzyme with a 3' to 5' exonuclease activity. The proof reading enzyme removes 
mismatched nucleotides as they are incorporated and replace them with the correct 
nucleotides, thus allowing Taq polymerase to continue amplifying the target DNA. The 
presence of both enzymes significantly improves fidelity and processivity which results 
in high yields of highly accurate.   
Moreover, in order to study the substitution of nucleotides, new primers 
could be designed to fix the differences in these nucleotide and subsequent amino acid 
sequences after overlapping the three fragments of the gene.  
In conclusion, the purpose of this research was to providing PSMA to be 
used at the expression point in Pichia pastoris. 
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Appendix 
 
Source: www.promega.com 
 
Source: www.invitrogen.com 
 
(a) The summary of features available on the pGEM-T and pPICZαA vectors used 
to clone the PSMA fragments into JM109 and Top10 competent cells 
respectively. 
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(b) Primers used for amplification of G1, G2 and G3 fragments of PSMA 
(overlapping extension). 
Fragment  Primers Primers Sequence 
G1 
 
a SfiPSMA-F 
PSMA-961R 
5'-cttcgggcccagccggccgatgtgcaatctccttcacgaaac-3' 
5'-gaagattccaaccatctggataggacttcac-3' 
b PSMA2Fo 
PSMA2Ro 
5’- tcttcgggtggtttataaaatcctcca-3’  
5’- aaattatataagaacttcttgatgttc-3’ 
c PSMA3Fo  
PSMA3Ro 
5’- cttatataattttacacagataccaca-3’ 
5’- gaaaatctcatttccatcttcattaat-3’ 
d PSMA4Fo 
PSMA4Ro 
G1d_oligo1 
 
G1d_oligo2 
G1d_oligo3 
 
5’- aatgagattttcaacacatcattattt-3’ 
5’- atcgccctctggcattccttgaggaga-3’ 
5’- AAT GAG ATT TTC AAC ACA TCA TTA 
TTT GAA CCA CCT CCT CCA GGA-3’ 
5’- CAC TGA AAG GTG GTA CAA TAT CCG 
AAA CAT TTT CAT ATC CTG GAG-3’ 
5’- CCA CCT TTC AGT GCT TTC TCT CCT 
CAA GGA ATG CCA GAG GGC GAT-3’ 
e PSMA5Fo 
PSMA5Ro 
5’- ccagagggcgatctagtgtatgttaac-3’ 
5’- tttaaccttatttcctctgaaaacttt-3’ 
f PSMA6Fo 
PSMA-961Ro 
5’- aataaggttaaaaatgcccagctggca-3’ 
 5’-attccaaccatctggataggacttcac-3’ 
 
G2 PSMA-961F 
PSMA-1741R 
5'-tccagatggttggaatcttcctggaggtggt-3' 
5'-gccactgaactctggggaaggacttttttta-3' 
G3 PSMA-800F 
PSMAfacXa-
Not1R 
5'-cttccccagagttcagtggcatgcccaggat-3' 
5'-agctggcggccgcgcggccttcaatggctacttcactcaaa-3' 
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(c) Full sequence of PSMA G1, G2 and G3 
 
G1 sub-fragment sequences 
 
FRAGMENT A 
ATGTGGAATCTCCTTCACGAAACCGACTCGGCTGTGGCCACCGCGCGCCGCCCGCGCTGGCT
GTGCGCTGGGGCGCTGGTGCTGGCGGGTGGCTTCTTTCTCCTCGGCTTCCTCTTC 
 
FRAGMENT B 
GGGTGGTTTATAAAATCCTCCAATGAAGCTACTAACATTACTCCAAAGCATAATATGAAAGC
ATTTTTGGATGAATTGAAAGCTGAGAACATCAAGAAGTTCTTATA 
 
FRAGMENT C 
TAATTTTACACAGATACCACATTTAGCAGGAACAGAACAAAACTTTCAGCTTGCAAAGCAA
ATTCAATCCCAGTGGAAAGAATTTGGCCTGGATTCTGTTGAGCTAGCACATTATGATGTCCT
GTTGTCCTACCCAAATAAGACTCATCCCAACTACATCTCAATAATTAATGAAGATGGAAATG
AG 
 
FRAGMENT D 
ATTTTCAACACATCATTATTTGAACCACCTCCTCCAGGATATGAAAATGTTTCGGATATTGTA
CCACCTTTCAGTGCTTTCTCTCCTCAAGGAATGCCAGAG 
 
FRAGMENT E 
GGCGATCTAGTGTATGTTAACTATGCACGAACTGAAGACTTCTTTAAATTGGAACGGGACAT
GAAAATCAATTGCTCTGGGAAAATTGTAATTGCCAGATATGGGAAAGTTTTCAGAGGAAAT
AAG 
 
FRAGMENT F 
GTTAAAAATGCCCAGCTGGCAGGGGCCAAAGGAGTCATTCTCTACTCCGACCCTGCTGACTA
CTTTGCTCCTGGGGTGAAGTCCTATCCAGATGGTTGGAATCTTCCTGGAGGTGGTGTCCA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
GATATCCTAAATCTGAATGGTGCAGGAGACCCTCTCACACCGCAAATG 
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G2 fragment sequence 
GCAGGAgAcCCTCTCACACCAGGTTACCCAGCAAATGAATATGCTTATAGGCGTGGAATT 
GCAGAGGCTGTTGGTCTTCCAAGTATTCCTGTTCATCCAATTGGATACTATGATGCACAG 
AAGCTCCTAGAAAAAATGGGTGGCTCAGCACCACCAGATAGCAGCTGGAGAGGAAGTCTC 
AAAGTGCCCTACAATGTTGGACCTGGCTTTACTGGAAACTTTTCTACACAAAAAGTCAAG 
ATGCACATCCACTCTACCAATGAAGTGACAAGAATTTACAATGTGATAGGTACTCTCAGA 
GGAGCAGTGGAACCAGACAGATATGTCATTCTGGGAGGTCACCGGGACTCATGGGTGTTT 
GGTGGTATTGACCCTCAGAGTGGAGCAGCTGTTGTTCATGAAATTGTGAGGAGCTTTGGA 
ACACTGAAAAAGGAAGGGTGGAGACCTAGAAGAACAATTTTGTTTGCAAGCTGGGATGCA 
GAAGAATTTGGTCTTCTTGGTTCTACTGAGTGGGCAGAGGAGAATTCAAGACTCCTTCAA 
GAGCGTGGCGTGGCTTATATTAATGCTGACTCATCTATAGAAGGAAACTACACTCTGAGA 
GTTGATTGTACACCGCTGATGTACAGCTTGGTACACAACCTAACAAAAGAGCTGAaAAGC 
CCTGATGAAGGCTTTGAAGGCAAATCTCTTTATGAAAGTTGGACTAAAAAAAGTCCTTCC 
CCAGA 
 
G3 fragment sequence 
GTTCAGTGGCATGCCCAGGATAAGCAAATTGGGATCTGGAAATGATTTTGAGGTgtCTTC 
CAACGACTTGGAATTGCTTCAGGCAGAGCACGGTATACTAAAAATTGGGAAACAAACAAA 
TTCAGCGGCTATCCACTGTATCACAGTGTCTATGAAACATATGAGTTGGTGGAAAAGTTT 
TATGATCCAATGTTTAAATATCACCTCACTGTGGCCCAGGTTCGAGGAGGGATGGTGTTT 
GAGCTAGCCAATTCCATAGTGCTCCCTTTTGATTGTCGAGATTATGCTGTAGTTTTAAGA 
AAGTATGCTGACAAAATCTACAGTATTTCTATGAAACATCCACAGGAAATGAAGACATAC 
AGTGTATCATTTGATTCACTTTTTTCTGCAGTAAAGAATTTTACAGAAATTGCTTCCAAG 
TTCAGTGAGAGACTCCAGGACTTTGACAAAAGCAACCCAATAGTATTAAGAATGATGAAT 
GATCAACTCATGTTTCTGGAAAGAGCATTTATTGATCCATTAGGGTTACCAGACAGGCCT 
TTTTATAGGCATGTCATCTATGCTCCAAGCAGCCACAACAAGTATGCAGGGGAGTCATTC 
CCAGGAATTTATGATGCTCTGTTTGATATTGAAAGCAAAGTGGACCCTTCCAAGGCCTGG 
GGAGAAGTGAAGAGACAGATTTATGTTGCAGCCTTCACAGTGCAGGCAGcTGCaGAGACT 
TTGAGTGAAGTAGCCATTGAAGGCCGC 
